DUBLIN, Feb. 13, 2015 /PRNewswire/ -- Actavis plc, a leading global specialty pharmaceutical company, today announced the launch of the "Unconditional Love" campaign, which recognizes the "unconditional love" shared by patients with Alzheimer's disease and their caregivers. In partnership with caregiver Betsy Broyles and the "The Love Architect" expert Kailen Rosenberg, Actavis honors the more than 15 million people in the United States that provide care to a loved one with Alzheimer's Disease or other dementia.2
Alzheimer's Disease is a progressive neurological disease, characterized by problems with memory, thinking and behavior.1 More than 5 million people in the United States are currently living with Alzheimer's Disease; it is also estimated that by 2050, the number of people age 65 years and older with Alzheimer's disease may triple to 16 million. 2 In addition, every 67 seconds, someone in the United States develops Alzheimer's disease.2
"Caregiving is a different kind of love that most people don't expect to experience," says caregiver Betsy Broyle. "Caregiving requires you to take on many different roles; but in doing so, the "unconditional love" you provide ensures that your loved one is treated properly. In turn, you begin to understand, address and properly respond to your loved one's needs."
As part of this campaign, Actavis will launch www.AlzheimersUnconditionalLove.com, a new website that provides disease education and additional information about the "unconditional love" campaign.
"Each year on Valentine's Day, we celebrate the romantic loves in our lives, honoring them and toasting to a lifetime of love. But too often the love of a caregiver is under appreciated," says "The Love Architect" expert Kailen Rosenberg. "I'm excited to partner with Actavis on this unique campaign to elevate the importance of caregivers and the 'unconditional love' they provide."
To learn more about the "Unconditional Love" campaign, caregivers are encouraged to visit this website: www.AlzheimersUnconditionalLove.com.
About Alzheimer's Disease
Alzheimer's disease is a progressive, neurodegenerative disorder characterized by problems with memory, thinking and behavior that eventually become severe enough to affect daily tasks. An estimated 5.2 million people in the United States are currently living with Alzheimer's disease. Alzheimer's disease is the fifth leading cause of death in the United States among those aged 65 and older and was reported as an underlying cause of death for more than 83,000 Americans in 2010.
About Kailen Rosenberg
Known as "The Love Architect," Kailen Rosenberg is more than just a matchmaker but a teacher of "love on a higher level." Hailed as a "Love Ambassador" by Oprah Winfrey, she's been featured as a regular guest on more than 400 print, on-line, radio and television interviews, including Today Show, Good Moring America, Cosmopolitan, Men's Fitness, Marie Claire, Redbook, Self, Oprah.com, the Oprah Winfrey Network, BBC Worldwide, E4, The Huffington Post and more.
About Betsy Broyles Arnold
Betsy is the daughter of football icon Coach Frank Broyles who, along with her twin sister, Linda, became the primary caregiver to their mother, Barbara, who lost her battle with Alzheimer's disease in 2004. That experience led her -- together with her sister and father -- to create The Frank and Barbara Broyles Foundation to help families and caregivers who are caring for a loved one with Alzheimer's disease.
Actavis plc, headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.
Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women's health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.
For more information, visit Actavis' website at www.actavis.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Actavis' current expectations depending upon a number of factors affecting Actavis' business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Actavis' products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Actavis' periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis' Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements.
1. "What is Alzheimer's?" Alzheimer's Association. 2014. http://alz.org/alzheimers_disease_what_is_alzheimers.asp#symptoms. Accessed February 5, 2015.
2. "2014 Alzheimer's Disease Facts and Figures." Alzheimer's Association. 2014. http://alz.org/alzheimers_disease_facts_and_figures.asp. Accessed February 5, 2014.
SOURCE Actavis plc